(RTTNews) – Today’s dose informs you of the disappointing effects of AC Immune on Alzheimer’s trial, Actinium Pharma’s progress in acute myeloid leukemia study, Johnson
Read. . .
1. AC Immune TAURIEL joins EA’s failed trials
The actions of AC Immune SA (ACIU) fell more than 40% on Wednesday after the disappointing effects in a Phase II trial of the experimental drug Semorinemab in early Alzheimer’s disease (with controlled light), TAURIEL.
In the TAURIEL study, Semorinemab did not meet its number one efficacy endpoint in minimizing clinical evaluation of cash dementia (CDR-SB) compared to placebo. ) and the Alzheimer’s Cooperative Study Group – Daily Life Inventory Activities (ADCS-ADL) were also not met.
Another phase II of Semorinemab is underway in another patient population, moderate Alzheimer’s disease known as LAURIET.
ACIU closed Wednesday at $4. 80, down 44. 9%.
2. Actinium Pharma AML Trial
A key Iomab-B trial III is underway in patients with recurrent or refractory acute myeloid leukemia, who are 55 years of age or older, called SIERRA, with effects expected until the end of the year.
ATNM closed Wednesday’s consultation at $8. 91, down 9. 36%.
3. Cytokinetics Enters Second Cardiac Myosin Inhibitor in Clinical Trial
Cytokinetics Inc. (CYTK) has introduced a single-dose placebo-controlled CK-271 test in healthy adults.
The CK-271 Phase I test will come with 3 cohorts, with 8 healthy adults compatible with the cohort, randomly assigned to CK-271 or placebo. The number one objective of this clinical examination is to evaluate the protection and tolerability of CK-271 and the secondary objective is to evaluate the pharmacokinetic profile of CK-271 after exclusive upstream oral doses.
CYTK closed Wednesday at $21. 07, up 2. 38%.
4. Johnson COVID-19 Vaccine Candidate Vaccine
Johnson
ENSEMBLE will recruit up to 60,000 volunteers on 3 continents and examine the protection and efficacy of a single placebo vaccine dose in COVID-19 prevention.
The Advanced Biomedical Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) are running with the company to publish the ENSEMBLE study.
Johnson
The company plans to deliver the JNJ-78436735 vaccine for emergency use authorization in early 2021.
5. Pfizer seeks extended FDA approval for XALKORI
Pfizer’s request for Inc. de new additional drug (PFE) for XALKORI for the remedy of paediatric ALK patients positive with recurrent or refractory giant mobile anaplastic lymphoma was accepted for precedence review through the FDA, with a resolution scheduled for January 2021.
Large mobile anaplastic lymphoma is a rare type of non-Hodgkin’s lymphoma, divided into ALK-positive or ALK-negative disease. If approved, XALKORI would be the first biomarker-based remedy for high mobility pediatric alK-positive anaplastic lymphoma, Pfizer noted.
XALKORI is already approved for the treatment of patients with non-small mobile metastatic lung carcinoma whose tumors are ALK positive or ROS1 positive. The drug generated annual sales of $ 530 million for Pfizer in 2019, up from $ 524 million in 2018.
6. Actions that have had something new
ASLAN Pharmaceuticals Limited (ASLN) closed Wednesday at $1. 92, an increase of 16. 36%.
American Well Corporation (AMWL) closed Wednesday at $28. 50, an increase of 15. 38%.
Strong Biosciences Inc. (FBRX) closed Wednesday’s consultation at $46. 52, up 8. 19%.
Vaccinex Inc. (VCNX) closed Wednesday at $1. 86, down 19. 83%.